• ATM Inhibition, Macropinocytosis, and Cancer Metabolism

  2026-10-06

  Huang and colleagues show that ATM suppression can promote macropinocytosis, enabling cancer cells to acquire nutrients and persist under nutrient-poor conditions. The study connects DNA damage response signaling with metabolic adaptation and identifies branched-chain amino acid availability as a potential vulnerability, while leaving important questions about tumor type, model dependence, and clinical translation.

• FH1 and the Maturity of iHep Gene Models

  2026-10-06

  FH1 small molecule is best understood as a hepatocyte-maturation variable rather than a standalone endpoint enhancer. This article examines how FH1-associated iHep phenotypes could improve interpretation of controllable gene-expression studies while distinguishing vendor-reported findings from evidence in the 2026 LIRP study.

• LY294002: Evidence, Uses, and Limitations

  2026-10-05

  LY294002, also known as 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, is widely described as a reversible class I PI3K pathway probe. This overview separates supplier-reported properties from findings in a supplied peer-reviewed microglial study and explains what can—and cannot—be inferred about cancer, autophagy, apoptosis, and neuroinflammation research.

• EGCG Beyond Antioxidants: Translational Strategy

  2026-10-05

  (-)-Epigallocatechin gallate (EGCG) is best understood as a context-dependent, network-active research molecule rather than a generic antioxidant. This thought-leadership analysis examines its mechanistic rationale, the translational limits exposed by recent EGCG analog research, and how researchers can distinguish parent-compound biology from developable therapeutic potential.

• Olaparib in Mesothelioma: HRR Profiling and BRCAness

  2026-10-04

  Borchert et al. linked homologous recombination repair gene-expression patterns and BAP1-associated BRCAness to in-vitro sensitivity to olaparib in malignant pleural mesothelioma. The study supports a broader HRR-deficiency framework for biomarker research, while its cell-line and retrospective expression evidence does not establish clinical response rates or treatment recommendations.

• Relative and Fractional Viability in Cancer Research

  2026-10-03

  Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability capture related but non-equivalent aspects of anticancer drug response. Its central contribution is a framework for separating proliferative arrest from cell killing, improving interpretation of in vitro evidence without treating a single viability value as a complete measure of drug action.

• Actinomycin D Workflows for Nucleolar Stress

  2026-10-02

  Actinomycin D enables controlled transcription shutdown for RNA-decay measurements, apoptosis induction, and nucleolar stress experiments. This guide translates DDX24–NPM1 phase-behavior findings into practical assay designs while emphasizing dose control, solution handling, and interpretation limits.

• Trilaurin: From C12 Lipid to Translational Platform

  2026-10-01

  Trilaurin is more than a hydrophobic excipient. Its C12 architecture links lipase-driven matrix digestion, protease protection, enzymatic synthesis, and formulation strategy. This article translates evidence on Glycerol Tridodecanoate into practical guidance for researchers developing oral peptide and protein delivery systems, biocatalytic workflows, and next-generation lipid platforms.

• Olaparib and PARP Condensates in DNA Repair

  2026-10-01

  Olaparib and AZD2281 research can move beyond BRCA status by examining how PARP-generated poly(ADP-ribose), FUS, and ionic conditions organize DNA-repair condensates. This article translates recent phase-separation findings into practical assay and cancer research strategies.

• 0.4% Trypan Blue Solution Protocol

  2026-09-30

  This article provides a practical workflow for using 0.4% Trypan Blue Solution in cell viability measurement, routine cell counting, and selected cytotoxicity assay workflows. It is intended for research use only and does not replace validated diagnostic methods or provide definitive apoptosis and necrosis detection.

• Inflammation in Ischemic Stroke: Biomarkers to Therapy

  2026-09-30

  This 2025 review integrates the rapidly evolving inflammatory response after ischemic stroke with biomarker development and treatment research. Its main practical contribution is a temporally and biologically coherent framework that connects blood–brain barrier injury, immune signaling, diagnostic interpretation, prognosis, and therapeutic timing.

• FTO–FOXO1–m6A Control of ADSC Osteogenesis

  2026-09-29

  Wang et al. identify an FTO–FOXO1–RUNX2/PPARG pathway through which m6A modification influences adipose-derived stem cell osteogenesis. The study combines genetic, cellular, RNA-level, pharmacological, and in vivo evidence, while also highlighting why FTO-inhibiting drugs may affect cell-based bone regeneration.

• From SCP4 Biology to Precision DNA Assays

  2026-09-29

  SCP4 research clarifies how H3T3 dephosphorylation supports mitotic fidelity. This thought-leadership guide translates that mechanistic insight into a disciplined assay strategy, showing where 2-Thio-dCTP can strengthen polymerase, DNA modification, and DNA–protein interaction studies while clearly separating biochemical utility from direct cellular or clinical claims.

• Triazole ALDH2 Activators for Myocardial Ischemia

  2026-09-28

  The reference study reports a structure-guided triazole series that activates aldehyde dehydrogenase 2 and addresses a central mechanism of myocardial ischemia-reperfusion injury. Its lead compound, Z17, combined strong ALDH2 activation with improved water solubility and protected cardiac structure and function in a mouse model, while still requiring broader pharmacological and translational validation.

• LY294002 Workflows for PI3K–Autophagy Research

  2026-09-28

  Use LY294002 to test whether PI3K/Akt/mTOR activity contributes to a cellular phenotype—not as a stand-alone proof of pathway specificity. A gouty-arthritis study offers a timely example, while practical dose controls and autophagy-flux measurements help distinguish pathway effects from toxicity or context-dependent responses.

8603 records 1/574 page Next 12345 下5页 Last page